As number of COVID-19 cases in Russia crossed 500,000, the government has rolled out a drug to treat the novel coronavirus even though clinical trials are still underway.
The country's health ministry has approved the use of the anti-viral drug, registered under the name Avifavir, under a special accelerated process.
In a press release, the state financial backer said the drug has been delivered to some hospitals and clinics in the country.
The country's RDIF sovereign wealth fund has a 50 per cent share in a joint venture with the drug's manufacturer ChemRar.
There is currently no vaccine for COVID-19, with human trials of several existing antiviral drugs yet to show efficacy.
So far, the country has 502,436 positive cases and the death toll stands at 6,532.
US, Iran at odds on nuclear inspections, frozen assets in deal to end war
Oman establishes temporary shipping corridor through Strait of Hormuz
Power cuts in France leave thousands sweltering amid scorching heatwave
Libya's eastern government bans entry of nationals from four African countries
New Lebanon-Israel talks begin in shadow of US-Iran deal
